This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Accepting new patients
The primary objective of this study is to evaluate the overall response rate (confirmed and unconfirmed, complete and partial) associated with rucaparib in patients with genomic LOH high and/or deleterious BRCA1/2 mutations within:
Note: This is only a partial list of eligibility criteria.
To be included in this trial:
Accepting new patients
Learn more at
Principal Investigator(s)
Bruce Gershenhorn
Patricia Rich
Theodore Pollock